



State of New Jersey

DEPARTMENT OF HEALTH

DIVISION OF EPIDEMIOLOGY, ENVIRONMENTAL AND OCCUPATIONAL HEALTH

PO BOX 369

TRENTON, N.J. 08625-0369

CHRIS CHRISTIE  
Governor

[www.nj.gov/health](http://www.nj.gov/health)

KIM GUADAGNO  
Lt. Governor

CATHLEEN D. BENNETT  
Acting Commissioner

August 13, 2015

**Availability of Meningococcal B Vaccines for VFC and 317 Program Providers**  
**&**  
**New ACIP Recommendations for Use of Meningococcal B**

The New Jersey Vaccines for Children (VFC) Program is pleased to announce the availability of the Meningococcal B vaccines Bexsero (GSK) and Trumenba (Pfizer) for all VFC and 317-Funded Adult (317) Program providers. Meningococcal B vaccine should be administered in accordance with recent Advisory Committee on Immunization Practices (ACIP) recommendations.

At its meeting in February 2015, the ACIP voted to recommend the use of serogroup B vaccines for people 10 and older in certain specific risk groups. These include:

- Persons who have persistent complement component deficiencies;
- Persons who have anatomic or functional asplenia, including sickle cell disease;
- Persons identified to be at increased risk because of a meningococcal disease outbreak attributable to serogroup B; and
- Microbiologists who are regularly exposed to *Neisseria meningitidis*.

In June 2015, the ACIP declined to vote to approve routine use of serogroup B meningococcal vaccine in young people, instead leaving the decision to doctors and their patients. ACIP voted that a serogroup B meningococcal vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. This recommendation is labeled as "Category B" meaning that individual clinical decision making is recommended. This recommendation expands the ACIP recommendations set forth in February.

Questions? Call VFC at 609-826-4862